Literature DB >> 21494796

Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.

Ralph Wäsch, Thilo Jakob, Kristin Technau, Jürgen Finke, Monika Engelhardt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494796     DOI: 10.1007/s00277-011-1235-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  Ixazomib-Associated Skin Exfoliation.

Authors:  Yali Zhang; Long Zhao; Yuancheng Guo; Bei Liu
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

2.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

3.  Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.

Authors:  Sarolta Bojtine Kovacs; Jingting Luan; Sandra Maria Dold; Andreas Weis; Milena Pantic; Justus Duyster; Ralph Wäsch; Monika Engelhardt
Journal:  Haematologica       Date:  2019-08-29       Impact factor: 9.941

4.  Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.

Authors:  Anupam Das; Amrita Sil; Vivek Mishra; Nilay Kanti Das
Journal:  Indian J Pharmacol       Date:  2014 Sep-Oct       Impact factor: 1.200

Review 5.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.